D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $20.00 price objective on the stock.

OS Therapies Trading Up 4.5%

Shares of NYSEAMERICAN:OSTX traded up $0.06 during midday trading on Friday, reaching $1.43. 481,348 shares of the company were exchanged, compared to its average volume of 576,358. The stock has a market cap of $50.39 million, a PE ratio of -1.75 and a beta of -3.80. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.68. OS Therapies has a one year low of $1.12 and a one year high of $2.57.

Institutional Investors Weigh In On OS Therapies

Large investors have recently made changes to their positions in the company. State Street Corp raised its holdings in OS Therapies by 16.3% during the 4th quarter. State Street Corp now owns 58,500 shares of the company’s stock valued at $82,000 after buying an additional 8,200 shares during the period. Jane Street Group LLC purchased a new stake in shares of OS Therapies in the fourth quarter valued at $39,000. Geode Capital Management LLC raised its stake in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after acquiring an additional 58,350 shares during the period. Susquehanna International Group LLP bought a new stake in shares of OS Therapies in the 3rd quarter worth about $29,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the 3rd quarter worth about $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.